Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Meanwhile, CVS Caremark, a major pharmacy benefit manager, announced that it would make Novo Nordisk’s popular weight-loss drug, Wegovy, its preferred GLP-1 therapy for weight loss, effective ...

Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies. May 1, 2025.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

CVS Caremark, the biggest U.S. pharmacy benefit manager, decided to highlight Wegovy as the preferred anti-obesity GLP-1 agonist on its standard formularies, or lists of covered drugs.

CVS Health owns the largest pharmacy benefit management (PBM) business in the United States. In its earnings report, Novo Nordisk management said it did not approach CVS about exclusivity.

As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration and licencing deal worth up to $2.2bn with the US-based biotech Septerna. The companies ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S ...